Trial reportBritish journal of cancer2016
Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee.
Trial report in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Moderate hypofractionated radiotherapy is more effective and safe for localized prostate cancer patients: a meta-analysis.Oncotarget · 2017Pooled it
- Trial
- Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.Health technology assessment (Winchester, England) · 2020Trial
- Trial
- Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial.Lancet (London, England) · 2017Trial
- Characteristics and outcomes of men presenting with complications of metastatic prostate cancer.BJU international · 2026Article
- National trends in bone-metastatic prostate cancer mortality in the United States, 1999-2024: a multiple-cause-of-death analysis with projections to 2040.Frontiers in oncology · 2026Article
- Assessing the Cause of Death for Men with Prostate Cancer Using Official Mortality Statistics or a Dedicated Cause of Death Committee: Results from 30-year ERSPC Rotterdam Data.European urology open science · 2025Article
- Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018.Transplantation and cellular therapy · 2024Article
- Mortality from leading cancers in districts of England from 2002 to 2019: a population-based, spatiotemporal study.The Lancet. Oncology · 2024Article
- Qualitative analysis of the coding of pathological data of cancer registry centers: A study in North of Iran.PloS one · 2023Article
- Mortality due to urolithiasis in England and Wales: updated findings from a national database over a 23-year period.Central European journal of urology · 2023Article
- Factors Associated with Major Errors on Death Certificates.Healthcare (Basel, Switzerland) · 2022Article
- Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer.European urology open science · 2021Article
- Article
- The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression.BJU international · 2020Article
- Comparison of Minimally Invasive Tissue Sampling With Conventional Autopsy to Detect Pulmonary Pathology Among Respiratory Deaths in a Resource-Limited Setting.American journal of clinical pathology · 2019Article
- Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model.PLoS medicine · 2019Article
- Disparities in place of death for patients with hematological malignancies, 1999 to 2015.Blood advances · 2019Article
- Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer.World journal of urology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 15 institutions in 3 countries.
Funding
Abstract
backgroundAccurate cause of death assignment is crucial for prostate cancer epidemiology and trials reporting prostate cancer-specific mortality outcomes.
methodsWe compared death certificate information with independent cause of death evaluation by an expert committee within a prostate cancer trial (2002-2015).
resultsOf 1236 deaths assessed, expert committee evaluation attributed 523 (42%) to prostate cancer, agreeing with death certificate cause of death in 1134 cases (92%, 95% CI: 90%, 93%). The sensitivity of death certificates in identifying prostate cancer deaths as classified by the committee was 91% (95% CI: 89%, 94%); specificity was 92% (95% CI: 90%, 94%). Sensitivity and specificity were lower where death occurred within 1 year of diagnosis, and where there was another primary cancer diagnosis.
conclusionsUK death certificates accurately identify cause of death in men with prostate cancer, supporting their use in routine statistics. Possible differential misattribution by trial arm supports independent evaluation in randomised trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.